F. Lordick

Discipline

Psychologie (2) Sociologie (1) Science politique (1) Linguistique (1) Economies et finances (1)

Type de document

Articles (11) Recensions (5)

Co-auteur

Date

Source

Mot-clé

Cancer (9) cancer (8) Cancer (8) Treatment (7) Patients (7) Human beings (7) Patients (7) gestion (6) Management (6) Management (6) oncologie (5) maladie (5) survie (5) Survival (5) Oncology (5) maladie (5) Europe (4) procès (4) Europe (4) Diagnosis (4) Surgery (4) Chemotherapy (4) Surgery (4) Europe (4) Diagnosis (4) Chemotherapy (4) thérapie (3) norme (3) taux (3) Control (3)

Documents écrit par F. Lordick (11) | parle de F. Lordick (0)

Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.
T.E. Kroese et al.
Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer.
T.E. Kroese et al.
Primary and metastatic peritoneal surface malignancies.
D. Cortés-Guiral et al. (16 déc. 2021)
Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians.
G. Chazan et al.
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology.
L. Castelo-Branco et al.
ESMO pays tribute to Professor José Baselga.
S. Peters et al.
Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians.
G. Chazan et al.
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.
G. Curigliano et al.
Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.
A.D. Wagner et al.
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
A.D. Wagner et al. (24 mai 2019)
VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study.
E. Smyth et al. (2019)